Therapeutic Strategies and Patient Demographics: A Deep Dive into the US Calciphylaxis Market
The US Calciphylaxis Market is the largest and most valuable globally, driven by the high prevalence of End-Stage Renal Disease (ESRD) and a substantial volume of patients receiving long-term dialysis. Calciphylaxis, a severe and life-threatening microvascular occlusion disorder, presents a critical unmet medical need within the US healthcare system. The key patient population consists predominantly of obese, female, Caucasian patients with hyperparathyroidism or mineral metabolism disorders, almost exclusively those with advanced CKD. The US market's high expenditure on specialized care, including extensive wound care, pain management, and nutritional support, contributes significantly to the market size. Currently, the therapeutic landscape in the US is dominated by off-label use of sodium thiosulfate (STS), which is the most common pharmacological intervention, administered intravenously, often during dialysis sessions. Other therapeutic strategies include parathyroidectomy for severe hyperparathyroidism, and the discontinuation of contributing…